A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Carcinoma; Inflammatory breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 12 Sep 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 12 Sep 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 09 Dec 2023 Status changed from active, no longer recruiting to discontinueddue to lack of efficacy in cohort 2 and the changing landscape of metastatic breast cancer therapies.